

Supplementary Table S1. Remifentanil-propofol mixture use in the clinical or laboratory studies.

Study (n)	Type of procedure	The concentration of RP mixture
2004, Berkenbosch et al. ⁴ (n=15)	Fiberoptic bronchoscopy	R (15-20 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2005, Tsui et al. ⁵ (n=56)	MRI	R (10 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2013, Pedersen et al. ⁶ (n=120)	MRI	R (10 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2020, Lai et al. ⁷ (n=236)	Colonoscopy	R (2.5 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2008, Mandel et al. ⁸ (n=50)	Colonoscopy	R (10 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2012, Joo et al. ⁹ (n=75)	Breast biopsy	R (25 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2001, Joo et al. ¹⁰ (n=120)	Shock wave lithotripsy	R (10 µg.ml ⁻¹) and P (5 mg.mL ⁻¹)
1999, Fish et al. ¹¹ (n=71)	Daycase urological surgery	R (2.5 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2014, Goudra et al. ¹² (n=1)	Recurrent radiation therapy	R (5 µg.ml ⁻¹) and P (5 mg.mL ⁻¹)
2012, Kramer et al. ¹⁴ (n=37)	Dental extraction	R (5 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2012, Mazanikov et al. ¹⁵ (n=81)	ERCP	R (20 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2005, Brady et al. ¹⁶ (n=49)	Ambulatory surgery	R (25 µg.ml ⁻¹) and P (5 mg.mL ⁻¹)
2020, Bagshaw et al. ¹⁷ (n=873)	Variety of procedures	R (5 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2021, Bakan et al. ¹⁸ (n=96)	Thyroidectomy	R (20 or 30 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2000, Stewart et al. ²⁰ (n=12)	A laboratory study	R (5 or 50 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2020, Henkel et al. ³⁹ (n=3)	A laboratory study	R (10-50 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)
2022, Wylie et al. ⁴⁰ (n=5)	A laboratory-based study	R (5 µg.ml ⁻¹) and P (10 mg.mL ⁻¹)

MRI: magnetic resonance imaging; ERCP: endoscopic retrograde cholangiopancreatography;
R: remifentanil; P: propofol.